Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2018-05-24 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-05-24 English
PRIMARY DOCUMENT
Director's Dealing
2018-05-24 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text indicates it is a short filing (2591 characters) and mentions a press release attached as Exhibit 99.1. There is no substantive financial data or detailed report content within the text itself, only a reference to an attached press release. According to the 'Menu vs Meal' rule, such a short document that announces or attaches another report or press release should be classified as a Regulatory Filing (RNS), not as the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2018-05-14 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2018, by Galectin Therapeutics Inc. It announces the results of operations and financial condition for the three months ended March 31, 2018, and includes a press release as an exhibit. The text states that the information is being furnished, not filed, and incorporates a press release with financial results and a business update. The document is not a full quarterly or annual report but an initial announcement of quarterly financial results. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights. The document length is 4336 characters, which is consistent with a press release or earnings announcement rather than a full interim report. Therefore, the correct classification is ER with high confidence.
2018-05-11 English
FORM 10-Q
Interim / Quarterly Report Q1 2018
2018-05-11 English
PRIMARY DOCUMENT
Director's Dealing
2018-04-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.